| Autor: |
Denis Querleu, Luis Paz-Ares, David R Baldwin, Denis Horgan, Stephen Hall, Alastair Kent, Chiara Benini, Iñaki Gutiérrez-Ibarluzea, Marina Chiara Garassino, Rocio Varea Mendez, Benjamin Horbach, Dipak Kalra, Gennaro Ciliberto, Beata Jagielska, Ettore Capoluongo, Penault-Llorca Frederique, Núria Malats, Pierfranco Conte, Jan van Meerbeeck, Ivica Belina, Fabrizia Galli, Angelo Paradiso, Fabien Calvo, Luis M. Montuenga, Jaafar Bennouna, William M. Gallagher, Peter Riegman, Vassiliki Fotaki, Hendrik van Poppel, Isabelle Ray-Coquard, Sarah Mee, Reinhard Büttner, Estelle Cauchin, Elisabetta Munzone, Ken Mastris, Anders Bjartell, Westphalen Christoph Benedikt, Susana Banerjee, Christa M. Cobbaert, Elzbieta Sarnowska, Michael Joe Duffy, Jasmina Koeva-Balabanova, Keith Kerr, Giovanni Codacci-Pisanelli, Benjamin Gannon, Simonetta Buglioni, Giuseppe Curigliano, Z. Maravic, Luis Seijo |
| Rok vydání: |
2020 |
| Předmět: |
|
| Popis: |
Rapid and continuing advances in biomarker testing are not being matched by take-up in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre-eminently in many cancers, but also in an ever-wider range of conditions. One of the paradigmatic examples is BRCA1/2 testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, development is impeded by data deficiencies, and lack of policy alignment on standards, approval – and the role of real-world evidence in the process - and reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europe's industrial competitiveness and innovation require an appropriate policy framework – starting with an update to outdated recommendations. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
